SYRS Syros Pharmaceuticals, Inc.

0  -3%
Previous Close 16.21
Open 16.25
Price To book 4.70
Market Cap 369.13M
Shares 23,392,000
Volume 17,367
Short Ratio 6.88
Av. Daily Volume 26,852

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiated September 2016. Preliminary data due fall of 2017.
Relapsed or refractory Acute myeloid leukemia (AML) and relapsed high-risk Myelodysplastic Syndrome (MDS) - cancer
Phase 1/2 trial to be initiated 1H 2017.
Acute leukemia - cancer

Latest News

  1. Syros to Present on Its Pioneering Approach to Identify Novel Drug Targets Linked to Genomically Defined Subsets of Patients at IMPAKT Breast Cancer Conference
  2. Syros Closes $35 Million Private Financing
  3. Syros Announces $35 Million Private Placement
  4. Syros to Present on SY-1425, Its First-in-Class Selective RARα Agonist, in Oral Plenary Session at AACR Hematologic Malignancies Conference
  5. Syros Announces FDA Acceptance of IND to Advance SY-1365, Its First-in-Class Selective CDK7 Inhibitor, into Phase 1 Clinical Trial in Patients with Advanced Solid Tumors
  6. Syros Presents Data at AACR Further Supporting Clinical Potential of SY-1425, Its First-in-Class Selective RARα Agonist, for Genomically Defined AML and MDS Patients
  7. Syros Presents New Preclinical Data at AACR Showing Anti-Tumor Activity of SY-1365, Its First-in-Class Selective CDK7 Inhibitor, in Multiple Difficult-to-Treat Solid Tumors
  8. Can Syros Pharmaceuticals (SYRS) Run Higher on Strong Earnings Estimate Revisions?
  9. Can The Uptrend Continue for Syros Pharmaceuticals (SYRS)?
  10. Syros Pharmaceuticals Stock: 3 Reasons Why SYRS Is a Top Choice for Momentum Investors
  11. Syros Pharmaceuticals, Inc. :SYRS-US: Earnings Analysis: 2016 By the Numbers : March 21, 2017
  12. Syros Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
  13. Syros to Present New Data on Lead Drug Candidates, SY-1425 and SY-1365, and CDK12/13 Inhibitor Program at Upcoming AACR Annual Meeting
  14. Syros Pharmaceuticals to Present at Upcoming Investor Conferences
  15. Syros Reports Discovery of Novel Genomics Based Approach to Stratifying Patients with Acute Myeloid Leukemia at Cold Spring Harbor Conference
  16. Syros’ Drug Discovery Research in Immuno-Oncology Highlighted at UCSD Moores Cancer Center Symposium
  17. Syros Announces Publication in Cell Highlighting Gene Control as Important and Rapidly Progressing Area of Research for Yielding New Medicines to Treat Cancer
  18. Syros Pharmaceuticals to Present at 2017 BIO CEO & Investor Conference
  19. Syros Appoints Industry Leader Peter Wirth as Chair of Its Board of Directors
  20. Syros to Present at the 35th Annual J.P. Morgan Healthcare Conference